Scott Braunstein: Steve, you want to talk a little bit balance sheet and then I’ll talk a little bit about the assets.
Steve Pfanstiel: Absolutely. Yes. Good morning, Jay. Thanks for the call. In terms of the use of the proceeds and obviously in addition to the PRV, we brought in $30 million plus from the Sagard deal and obviously the offering we announced. All of those will go into continuing investment in our commercialization of ZTALMY, our continued investment in our clinical development, which includes the two Phase 3 trials we have ongoing, the RSE trial and the TrustTSC trial plus we’ll start a second European based RAISE trial next year. That’ll be a Phase 3 as well. And then general expenses in terms of working capital, capital expenditures as we build up our IV infrastructure as well. So those funds will kind of support all of those activities.
In terms of prioritization, I think we’ve been clear, the commercialization of ZTALMY is incredibly important. Obviously, we’re extremely focused on the Phase 3s we have going with the RSE readout expected second half the next year in Q1 for TSC. Those are just obvious critical priorities from an investment perspective. Scott, I’ll turn it back to you.
Scott Braunstein: Thanks, Steve. Jay, I think what you’re hearing from us is that we’re having a €“ we’re just really enjoying working in the ultra-orphan disease space. I think working with the advocacy groups and helping these patients get therapies for very severe conditions gets a lot of us through the day with a lot of excitement. There are challenges in the ultra-orphan disease business and I think the epilepsy space even more complicated, because these patients multiple medical conditions. But to the €“ my earlier points, I mean, we’re really seeing very strong reimbursement from the community from our payers and the opportunity to really share this information with physicians broadly. So we love this model and we would love to expand our presence in the space.
We think there are some really great targets out there. We’re spending more and more time looking at other mechanisms of action. We’re certainly still very invested in our second generation program, which we think can drive increased efficacy with a great side effect profile, which is so critical in these patients who are really suffering from so many other medical conditions. But we’re certainly happy that we can take some real resources and look at other assets in the space. And I think Christy and her team’s done a great job on the commercial side. And it would be great to think about adding another product to the portfolio over time. I think we’re incredibly focused on this launch and what we are very hopeful will be an important TSC launch in 25.
And of course, the RSE launch around the same time. So I think Christy seems got a lot on her plate. We’re thrilled to have a new commercial lead on the IV side of the business, who’s going to compliment our sales leadership on the oral side tremendously well. So most of our time today is looking at relatively early stage assets, nothing late stage in the epilepsy side. I think we’ve come pretty good at developing these drugs, and I feel incredibly fortunate that we have Joe, Dr. Ian Miller, who’s fantastic, a really a strong scientific team. We have another epileptologist on the team, who’s been just critically important on our payer side. So we’ve got some really strong intellectual fire power. And we’re doing our best to look at all the compounds that are out there.
